Our data point to a novel finding: that diet composition augments doxorubicin efficacy in FLT3‐ITD AML in vivo, indicating that a diet based behavioral modification concurrent with leukemia treatment may have clinical application. The gene discussed is FLT3; the disease is leukemia.